

The Former Yugoslav Republic of Macedonia

Tuberculosis profile

Population 2015

2.1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	<0.01 (<0.01–<0.01)	0.41 (0.37–0.44)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0 (0–0.01)
Incidence (includes HIV+TB)	0.27 (0.26–0.28)	13 (12–14)
Incidence (HIV+TB only)	<0.01 (<0.01–<0.01)	0.04 (0.03–0.04)
Incidence (MDR/RR-TB)**	<0.01 (<0.01–0.016)	0.44 (0.12–0.77)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.011 (<0.01–0.015)	0.093 (0.073–0.11)	0.1 (0.08–0.13)
Males	0.011 (<0.01–0.014)	0.16 (0.12–0.19)	0.17 (0.13–0.2)
Total	0.022 (0.017–0.026)	0.25 (0.24–0.26)	0.27 (0.26–0.28)

TB case notifications, 2015

Total cases notified	284
Total new and relapse	282
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	66%
- % pulmonary	79%
- % bacteriologically confirmed among pulmonary	87%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	100% (100–110)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.03 (0.03–0.04)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	0	0%
- on antiretroviral therapy	0	

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			6 (1–12)
Estimated % of TB cases with MDR/RR-TB	2.4% (0.65–6)	6.7% (0.17–32)	
% notified tested for rifampicin resistance	64%	65%	183
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 5, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 5, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	87%	281
Previously treated cases, excluding relapse, registered in 2014	100%	1
HIV-positive TB cases, all types, registered in 2014	0%	1
MDR/RR-TB cases started on second-line treatment in 2013	50%	2
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100–100)

TB financing, 2016

National TB budget (US\$ millions)	2.1
Funding source: 6% domestic, 94% international, 0% unfunded	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically